ReviewGynecologic oncology2015
Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies.
Review in Gynecologic oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 62 citations in OpenAlex.
- Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancer.Cancer · 2026Article
- Modelling the ageing dependence of cancer evolutionary trajectories.Nature reviews. Cancer · 2025Review
- Article
- Obese patients with malignant tumor: a case series and literature review.Discover oncology · 2025Article
- Impact of obesity‑associated myeloid‑derived suppressor cells on cancer risk and progression (Review).International journal of oncology · 2024Review
- Lipid Disturbances in Breast Cancer Patients during Chemotherapy.Nursing reports (Pavia, Italy) · 2023Article
- Obesity and cancer stem cells: Roles in cancer initiation, progression and therapy resistance.World journal of stem cells · 2023Review
- Chemotherapy and Anticancer Drugs Adjustment in Obesity: A Narrative Review.Current medicinal chemistry · 2023Review
- Article
- Obesity reduced survival with 5-fluorouracil and did not protect against chemotherapy-induced cachexia or immune cell cytotoxicity in mice.Cancer biology & therapy · 2022Article
- Nutritional Status at Diagnosis as Predictor of Survival from Childhood Cancer: A Review of the Literature.Diagnostics (Basel, Switzerland) · 2022Review
- Metabolic risk factors of ovarian cancer: a review.JBRA assisted reproduction · 2022Review
- The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy.Journal of biomedical science · 2022Review
- Excess Body Fatness during Early to Mid-Adulthood and Survival from Colorectal and Breast Cancer: A Pooled Analysis of Five International Cohort Studies.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Role of adipocytokines in endometrial cancer progression.Frontiers in pharmacology · 2022Review
- Tumour fatty acid metabolism in the context of therapy resistance and obesity.Nature reviews. Cancer · 2021Review
- Obesity and gynecological cancers: A toxic relationship.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2021Article
- Computed Tomography-Based Body Composition in Patients With Ovarian Cancer: Association With Chemotoxicity and Prognosis.Frontiers in oncology · 2021Article
- Article
- Obesity in Gynecologic Oncology.Geburtshilfe und Frauenheilkunde · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo describe the effects of obesity on the pharmacokinetics and dosing of chemotherapies and provide recommendations for chemotherapy management in obese women with gynecologic malignancies.
methodsPubMEd and MEDLINE databases were searched for articles published before June 2014. Only English-language articles were considered. 84 manuscripts were reviewed and 66 were included. Search terms included: obesity, overweight, body mass index, body surface area, glomerular filtration rate, chemotherapy, ovarian cancer, endometrial cancer, inflammation, and pharmacokinetics,
resultsObese cancer patients have worse clinical outcomes, compared with non-obese patients. This may be because of differences in pharmacokinetics, metabolic dysregulation, or physicians' decisions to reduce chemotherapy dose-intensity during treatment to minimize toxicities. A 2012 American Society of Clinical Oncology Clinical Practice Guideline recommends using actual body weight for chemotherapy dosing in all patients treated with curative intent, irrespective of obesity, to avoid compromising clinical outcomes, including progression free survival (PFS) and overall survival (OS). In women with gynecologic cancers most studies demonstrate no difference in PFS or OS when obese patients receive the same chemotherapy dose intensity as non-obese patients, except perhaps with bevacizumab.
conclusionsChemotherapy dose-intensity is a critical determinant of cancer outcomes and should be maintained in all patients, irrespective of obesity. Future studies should prospectively examine the impact of obesity on clinical outcomes (adverse events, survival) to improve the care of this growing population of patients who are at risk for inferior clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.